Test Price
2,800 AED✅ Home Collection Available
GRXCR1 Gene NGS Test for Autosomal Recessive Deafness Type 25 (DFNB25) – Dubai Healthcare City
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2022 Accredited Laboratory Processing
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for Result Interpretation by DHA-Licensed Consultant Medical Geneticist
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
This NGS-based test screens for mutations in the GRXCR1 gene responsible for autosomal recessive nonsyndromic hearing loss DFNB25, providing definitive molecular diagnosis and carrier detection for ENT specialists, audiologists, and clinical geneticists.
Test Overview & Methodology
The GRXCR1 Genetic Test employs targeted next-generation sequencing (NGS) to identify pathogenic variants in the GRXCR1 gene, the causative locus for DFNB25. This comprehensive single-gene analysis enables precise molecular confirmation of hereditary hearing loss, guiding accurate genetic counseling and informed family planning decisions.
| Feature | Our Test (NGS-Based) | Standard Sanger Sequencing |
|---|---|---|
| Precision | 99.9% analytical sensitivity for GRXCR1 variants | <95% due to limited resolution |
| Methodology | Targeted Next‑Generation Sequencing with full exon analysis | Capillary electrophoresis, gene‑by‑gene approach |
| Turnaround Time | 3–4 weeks | 6–10 weeks (multi-gene) |
Physician Insight & Safety Protocols
Genetic testing for hereditary hearing loss provides powerful diagnostic clarity, yet results must always be evaluated alongside comprehensive audiological assessments and detailed family history. As a DHA-licensed Consultant Medical Geneticist, I strongly advise discussing all findings with your referring specialist before making any medical decisions. This test is a tool for confirmation, not a standalone guide for intervention. – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Information
Important Clinical Advisory
Do not discontinue prescribed hearing aids, cochlear implants, or medical therapies based solely on genetic findings. Molecular results complement, not replace, ongoing clinical management of hearing loss.
Exclusion Criteria & Emergency Red Flags
Contraindications & Urgent Referral Indicators
- Exclusion: Active infection at the venipuncture site; inability to provide informed consent (pediatric patients require parental/guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability); unstable medical conditions requiring urgent intervention.
- ER Red Flags: Sudden hearing loss, severe vertigo, nystagmus, or signs of meningitis require immediate emergency evaluation—genetic testing does not substitute acute medical care.
Patient FAQ & Clinical Guidance
1. What conditions does the GRXCR1 Genetic Test detect?
This NGS test identifies pathogenic mutations in the GRXCR1 gene causing autosomal recessive nonsyndromic hearing loss DFNB25, providing definitive molecular diagnosis for affected individuals and reliable carrier detection for asymptomatic family members.
2. What is the expected turnaround time and total cost?
Results are delivered within 3 to 4 weeks from sample receipt. The total cost is 2,800 AED, inclusive of a post-test genetic counselling session conducted by our DHA-licensed Consultant Medical Geneticist.
3. Can I schedule a home blood collection, and does insurance cover this test?
Yes, we provide VIP mobile phlebotomy home collection daily from 8 AM to 11 PM. Our team assists with direct insurance billing verification via WhatsApp at +971 54 548 8731. Please contact us to confirm your specific coverage.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the governance of the Dubai Health Authority (DHA) and adheres to all applicable UAE federal laws governing diagnostic genetic testing and patient data protection. Patient genomic data is processed, stored, and transmitted in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures and consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability to ensure ethical and safe delivery of genetic testing services.
Clinical & Logistical Metadata
| Test Name | GRXCR1 Gene NGS Test for Autosomal Recessive Deafness Type 25 (DFNB25) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) – Full exon analysis |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 55324-5 |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians